The question of whether President Biden’s Department of Health and Human Services (HHS) is protecting drug companies instead of Alzheimer’s patients is complex and involves multiple layers of policy, economics, and healthcare priorities. To understand this issue, it’s important to…
Vaccines are designed to protect people from infectious diseases by stimulating the immune system to recognize and fight pathogens. For seniors, vaccines are especially important because aging often weakens the immune system, making older adults more vulnerable to infections and…
The question of whether Dr. Anthony Fauci’s legacy is tied to failed Alzheimer’s research funding involves examining his role, the broader context of biomedical research funding, and the specific challenges in Alzheimer’s disease research. Fauci, as the longtime director of…
Families are increasingly filing lawsuits against companies that market memory supplements with misleading claims about their effectiveness. These legal actions arise from concerns that some supplement manufacturers exaggerate or falsely advertise the benefits of their products, promising significant memory improvement…
The question of whether the FDA is approving Alzheimer’s treatments that don’t actually work is complex and has sparked significant debate. Several new drugs targeting Alzheimer’s disease have been approved in recent years, but their effectiveness and safety profiles have…
Pharmaceutical executives could potentially face criminal trials related to dementia drugs if evidence emerges that they engaged in illegal or unethical practices during the development, marketing, or distribution of these medications. This possibility arises from past precedents where pharma companies…
Medicare is not cutting Alzheimer’s coverage to hide rising costs, but the landscape of coverage and costs is evolving in ways that can feel confusing and challenging for patients and families. Medicare continues to provide important services for people with…
The question of whether nursing home deaths during COVID-19 are being covered up by the CDC is complex and involves multiple layers of public health policy, data reporting, and political controversy. There is no clear evidence that the CDC has…
The COVID-19 pandemic and the policies enacted to control it have likely accelerated cognitive decline in seniors through a combination of direct biological effects of the virus and indirect consequences of social isolation, stress, and disrupted routines. While the virus…
The question of whether Big Tech is censoring families talking about dementia drug injuries touches on a complex intersection of technology, health communication, corporate policies, and public discourse. There is growing concern among some groups that major technology platforms—such as…